Neurogenic Orthostatic Hypotension
Chelsea Therapeutics announces results of European Phase IIb trial of Droxidopa
Published in Medical Letter on the CDC and FDA, February 18th, 2007
The primary objective of the trial was to determine the optimal dose of Droxidopa in the treatment of orthostatic hypotension in patients with multiple system atrophy (MSA) or Parkinson disease (PD). The double-blind, randomized, placebo-controlled, parallel group, Phase IIb trial, led by Christopher Mathias, DPhil, DSc, FRCP, professor of neurovascular medicine, Imperial College School of Medicine at St. Mary's Hospital, London, was conducted at 30...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Hemosiderosis Therapy
Research reports from Center for Drug Evaluation and Research provide new insights into hemosiderosis therapy - Acromegaly
Tercica reports NDA for Somatuline Autogel for acromegaly accepted for filing by U.S. FDA - Angiology
ProRhythm initiates U.S. pivotal trial for HIFU ablation system - Antipsychotics
Evidence lacking to support many off-label uses of atypical antipsychotics - Avian Influenza
Tuttle joins HepaLife to expedite development of bird flu vaccine - Avian Influenza
U.S. Department of Health & Human Services funds advanced development of H5N1 influenza vaccines - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
